Article Details
Retrieved on: 2022-08-01 20:44:35
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The October 2018 cross-licence with Astrazeneca had seemed like a fresh start for Innate Pharma after the failure of the Bristol Myers ...
Article found on: www.evaluate.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here